Founder & COOJon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.
Crossmint has launched a new API that enables AI agents to make purchases using eligible Visa credit and debit cards, extending payment capabilities for autonomous software beyond cryptocurrency-based transactions.
President Donald Trump has signed an executive order directing federal agencies to expand the use of artificial intelligence in cybersecurity and establish a framework for reviewing advanced AI systems before their public release.
Ingenia Communities Group (ASX:INA) is on track to deliver earnings before interest and taxes of $180.5 million to $188.7 million.
A House of Lords committee has warned that parts of the Bank of England’s proposed stablecoin framework could undermine the viability of pound-denominated stablecoins despite supporting the introduction of regulation.
Artificial intelligence lab Anthropic has extended access to its Mythos model to Australian organisations.
INVO Fertility (NASDAQ:IVF) reported a 5% increase in total net revenue for fiscal year 2025, supported by steady expansion across its clinic network and a restructured balance sheet that eliminated several complex legacy equity liabilities.
Voyager Technologies (NYSE:VOYG) has signed a definitive agreement to acquire Astrobotic Technology, a privately held developer of commercial lunar delivery systems, surface power infrastructure, and reusable rockets.
Victoria’s Secret (NYSE:VSCO) reported a 15% increase in first-quarter net sales, fueled by a sharp recovery in consumer demand that prompted the apparel retailer to lift its financial projections for the full fiscal year.
Watsco (NYSE:WSO) has finalized its acquisition of Jackson Supply Company, a prominent distributor of heating, ventilation, and air conditioning (HVAC) equipment, significantly expanding its operational reach across the fast-growing U.S. Sunbelt region.
Travere Therapeutics (NASDAQ:TVTX) has entered into an exclusive licensing and collaboration agreement with Everest Medicines to develop and commercialize civorebrutinib, an experimental treatment targeting multiple immune-mediated rare kidney diseases.
